Spotlight On... Luminex bumps up offer for Nanosphere to $77M; WHO expands use for nonsurgical circumcision device; Nucleix gets $3M to back bladder cancer urine test; and more...

Luminex ($LMNX) had offered to buy molecular microbiology and diagnostic company Nanosphere ($NSPH) for $58 million. But it was forced to raise its offer to about $77 million after an unsolicited third party offered $1.50 per share for the company. The original offer was for $1.35 and the current agreed-upon offer is for $1.70 per share. More

> The World Health Organization (WHO) has expanded its prior prequalification for the PrePex male nonsurgical circumcision device to adolescents who are 13 years are older; the agency previously prequalified it for adult males. More

> Yissum Research Development Company of the Hebrew University of Jerusalem has received $1.2 million from Aurum Ventures to develop a diagnostic test for multiple diseases by analyzing circulating DNA released from dying cells. More

> Israeli epigenetic biomarker company Nucleix has raised $3 million to back its urine test for bladder cancer and to develop liquid biopsy tests for other cancers. The urine test is expected to receive a CE mark and start marketing in Europe next quarter. More

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.